Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$39.98 Current share price...
On May 30, 2024, Salvatore Privitera, Chief Technical Officer of AtriCure Inc (NASDAQ:ATRC), purchased 5,000 shares of the company, as reported in a recent SEC Filing.
MASON, Ohio, May 15, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference.